Ketamine News and Research RSS Feed - Ketamine News and Research

Study finds link between contraband cigarette and illicit drug use among teens in Canada

Study finds link between contraband cigarette and illicit drug use among teens in Canada

A University of Alberta economics professor has discovered a link between contraband cigarette use and illicit drug use among Canadian teens. [More]
Scientists receive NARSAD Distinguished Investigator Grants for mental health research

Scientists receive NARSAD Distinguished Investigator Grants for mental health research

The Brain & Behavior Research Foundation today announced the award of NARSAD Distinguished Investigator Grants valued at $1.5 million to 15 scientists, who are full professors or the equivalent, conducting innovative projects in diverse areas of neurobiological and behavioral research. [More]
Brain & Behavior Research Foundation to honor 8 scientists for achievements in psychiatric research

Brain & Behavior Research Foundation to honor 8 scientists for achievements in psychiatric research

The Brain & Behavior Research Foundation will honor eight scientists with its 2014 Outstanding Achievement Prizes for work delving into psychiatric disorders that affect one in four people. The awards, which celebrate the transformative power of neuroscience and psychiatric research to improve the lives of people with mental illness, will be presented at the Foundation's National Awards Dinner at the Pierre Hotel. [More]
RSAM, Rettsyndrome.org renew commitment to defeat Rett syndrome

RSAM, Rettsyndrome.org renew commitment to defeat Rett syndrome

Rett Syndrome Association of Massachusetts and Rettsyndrome.org are thrilled to announce today their renewed commitment to work together to defeat Rett syndrome. A generous $150,000 donation from RSAM will support a Rettsyndrome.org approved grant to Dr. Michela Fagiolini's project at the Boston Children's Hospital: "Assessing NMDA receptor (NMDAr) modulators to ameliorate cortical regression in Rett syndrome". [More]
New hope for people suffering from depression

New hope for people suffering from depression

There is new hope for people suffering from depression. Researchers have identified a compound, hydroxynorketamine (HNK), that may treat symptoms of depression just as effectively and rapidly as ketamine, without the unwanted side effects associated with the psychoactive drug, according to a study in the July issue of Anesthesiology, the official medical journal of the American Society of Anesthesiologists- (ASA-). [More]
Researchers develop rapid-acting antidepressants for treatment-resistant depression

Researchers develop rapid-acting antidepressants for treatment-resistant depression

UT Southwestern Medical Center researchers have generated fresh insights that could aid in the development of rapid-acting antidepressants for treatment-resistant depression. [More]
Naurex's two lead antidepressant programs achieve major milestones

Naurex's two lead antidepressant programs achieve major milestones

Naurex Inc., a privately held biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system (CNS), today announced that its two lead antidepressant programs achieved major milestones. [More]
IV-administered ketamine effective in patients with chronic PTSD

IV-administered ketamine effective in patients with chronic PTSD

For the first time, evidence that a single dose of IV-administered ketamine was associated with the rapid reduction of symptoms of post-traumatic stress disorder in patients with chronic PTSD was demonstrated in a proof-of-concept, randomized, double blind crossover study, undertaken by researchers at the Icahn School of Medicine at Mount Sinai in New York City. These findings, according to Mount Sinai researchers, could be the first step toward developing new interventions for PTSD. [More]
Intranasal ketamine spray confers rapid antidepressant effect in patients with depressive disorder

Intranasal ketamine spray confers rapid antidepressant effect in patients with depressive disorder

A research team from the Icahn School of Medicine at Mount Sinai published the first controlled evidence showing that an intranasal ketamine spray conferred an unusually rapid antidepressant effect -within 24 hours-and was well tolerated in patients with treatment-resistant major depressive disorder. [More]
Ketamine offers novel treatment for patients with severe depression

Ketamine offers novel treatment for patients with severe depression

New data show ketamine (a drug widely used for anaesthesia and pain relief) has a rapid antidepressant effect in some patients with severe depression. The first UK study of ketamine intravenous infusions in people with treatment-resistant depression was conducted by the Oxford Health NHS Foundation Trust and the University of Oxford. [More]
Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

Forest Laboratories, Inc., a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, today announced that it plans to discontinue the sale of NAMENDA (memantine HCl) 5 mg and 10 mg tablets effective August 15, 2014. [More]
New treatments for depression on the horizon

New treatments for depression on the horizon

New insights into the physiological causes of depression are leading to treatments beyond common antidepressants such as Prozac and Zoloft, researchers are reporting in the in the journal Current Psychiatry. [More]
PET imaging of brain reveals ketamine may act as antidepressant by regulating serotonin activity

PET imaging of brain reveals ketamine may act as antidepressant by regulating serotonin activity

​Ketamine is a potent anesthetic employed in human and veterinary medicine, and sometimes used illegally as a recreational drug. The drug is also a promising candidate for the fast treatment of depression in patients who do not respond to other medications. [More]
Portage acquires approximately 54% equity in Biohaven

Portage acquires approximately 54% equity in Biohaven

Portage Biotech Inc., is pleased to announce that it has acquired approximately 54% equity in Biohaven Pharmaceutical Holding Company Limited, a private corporation formed under the laws of the British Virgin Islands, for $3.5 million, payable as $1.75 million upfront and the balance in three installments over the next eleven months. [More]
Chemists able to trace narcotics substances, prescription drugs in Swedish wastewater

Chemists able to trace narcotics substances, prescription drugs in Swedish wastewater

Chemists at Ume- University in Sweden have been able to trace narcotics substances and prescription drugs in measurements of wastewater from 33 Swedish sewage treatment plants. Cocaine, amphetamine, and methamphetamine, in measurable concentrations, were found in a total of half of the locations. [More]

Researchers analyze effects of MXE drug usage

Researchers from Sweden have attempted to create an understanding to the subjective effects from use of Methoxetamine (MXE), a drug belonging to a class known as "legal highs" or "research chemicals," and available for purchase on the Internet. [More]
Enhancing the NMDA glutamate receptor causes antidepressant-like effects

Enhancing the NMDA glutamate receptor causes antidepressant-like effects

Thirteen years ago, an article in this journal first reported that the anesthetic medication, ketamine, showed evidence of producing rapid antidepressant effects in depressed patients who had not responded to prior treatments. Ketamine works by blocking one of the targets for the neurotransmitter glutamate in the brain, the N-methyl-D-aspartate (NMDA) glutamate receptor. [More]
mTOR protein: A key mediator of antidepressant effects of ketamine

mTOR protein: A key mediator of antidepressant effects of ketamine

Two years ago, mammalian target of rapamycin or mTOR, a signaling protein, was identified as a key mediator of the antidepressant effects of ketamine, the first rapidly acting antidepressant medication to be identified. [More]
Brain & Behavior Research Foundation announces recipients of NARSAD Investigator Grants

Brain & Behavior Research Foundation announces recipients of NARSAD Investigator Grants

The Brain & Behavior Research Foundation (formerly known as NARSAD, the National Alliance for Research on Schizophrenia and Depression), under the direction of Dr. Jeffrey Borenstein, President & CEO, has announced the latest recipients of its NARSAD Distinguished Investigator Grants. [More]

Serotonin 2C receptors induce fast-acting antidepressant effects in mice

More than 1 in 10 Americans take antidepressants, but these medications can take weeks-and for some patients, months-before they begin to alleviate symptoms. Now, scientists from the University of Chicago have discovered that selectively blocking a serotonin receptor subtype induces fast-acting antidepressant effects in mice, indicating a potential new class of therapeutics for depression. The work was published Oct. 29 in Molecular Psychiatry. [More]